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The use of biomaterials and signaling molecules to induce bone formation is a promising
approach in the field of bone tissue engineering. Follistatin (FST) is a glycoprotein able to
bind irreversibly to activin A, a protein that has been reported to inhibit bone formation.We
investigated the effect of FST in critical processes for bone repair, such as cell recruitment,
osteogenesis and vascularization, and ultimately its use for bone tissue engineering.
In vitro, FST promoted mesenchymal stem cell (MSC) and endothelial cell (EC) migration
as well as essential steps in the formation and expansion of the vasculature such as
EC tube-formation and sprouting. FST did not enhance osteogenic differentiation of
MSCs, but increased committed osteoblast mineralization. In vivo, FST was loaded in
an in situ gelling formulation made by alginate and recombinant collagen-based peptide
microspheres and implanted in a rat calvarial defect model. Two FST variants (FST288
and FST315) with major differences in their affinity to cell-surface proteoglycans, which
may influence their effect upon in vivo bone repair, were tested. In vitro, most of the loaded
FST315 was released over 4 weeks, contrary to FST288, which was mostly retained
in the biomaterial. However, none of the FST variants improved in vivo bone healing
compared to control. These results demonstrate that FST enhances crucial processes
needed for bone repair. Further studies need to investigate the optimal FST carrier for
bone regeneration.
Keywords: follistatin 315 (FST315), follistatin 288 (FST288), migration, vascularization, osteogenesis, injectable in
situ gelling slow release system, bone tissue engineering, regenerative medicine
INTRODUCTION
Biomaterial scaffolds functionalized to stimulate endogenous repair mechanisms incorporating
bone-forming factors offer a potential alternative to bone-grafts. Furthermore, injectable systems
are a promising option since they can potentially deliver growth factors in a less invasive manner
and conform to complex shapes, which is especially important within the craniofacial complex
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(Kretlow et al., 2009). Therefore, choosing the right material
and growth factor(s) is critical to induce the key events needed
for bone formation. In previous work, we have developed an
in situ gelling formulation made by alginate and Recombinant
Collagen-based Peptide (RCP) microspheres (MS) that were able
to considerably slow down the release of bone morphogenetic
protein 2 (BMP-2) and support bone formation (Mumcuoglu
et al., 2018). However, despite the therapeutic potential of BMP-2
in bone repair, it is not free of complications such as ectopic bone
formation, respiratory failure, inflammation, pseudarthrosis, and
cancer (Poon et al., 2016).
The TGF-β family comprises more than 30 signaling
proteins that are essential developmental factors stimulating
diverse cellular differentiation and growth responses (Hinck
and Huang, 2013). Among them, bone morphogenetic proteins
(BMPs) and the activin/inhibin subfamily members such as
BMP-2 or activins have been shown to be fundamental in
the regulation of bone organogenesis (Abe et al., 2004b;
Rahman et al., 2015). Particularly, activin A is one of the
most abundant TGF-β family member proteins found in
bone (Pearsall et al., 2008). Consequently, bone contains
high concentrations of BMPs and activins as well as their
antagonists such as noggin or follistatin (FST), which block
signaling and are essential regulators of endogenous bone repair.
Their importance is such that Matzuk et al. demonstrated
that follistatin-deficient mice were growth-retarded and among
others showed skeletal defects, dying within hours of birth
(Matzuk et al., 1995). The effect of FST on bone repair
and the major target it antagonizes, activin A, is not clear.
It has been previously reported that activin A stimulates
osteoclast formation (Sakai et al., 1993; Koseki et al., 2002), and
that the administration of soluble activin receptors enhances
bone formation and bone mineral density in both mice
and monkeys (Pearsall et al., 2008; Fajardo et al., 2010;
Bialek et al., 2014).
In bone, FST is mainly expressed by osteoblasts, but also to a
lesser extent by osteocytes in both developing mouse mandible
and in the callus of repairing bone (Inoue et al., 1994). Its role in
osteogenic differentiation is controversial, both a positive and a
negative effect upon osteoblasts during osteogenic differentiation
have been reported (Abe et al., 2004a; Eijken et al., 2007). In
vivo, several studies have used follistatin-overexpressing mice
to assess its effect upon muscle healing and bone morphology,
concluding that FST improved muscle healing after injury, but
its overexpression leads to a decreased quality of the skeleton
(Zhu et al., 2011; Gajos-Michniewicz et al., 2012). Kawao et al.
have demonstrated that in response to hyper gravity, FST acts as
a circulating molecule regulating muscle and bone metabolism
and the interaction between them (Kawao et al., 2017). Taken
together, these data suggest that FST administration, as the
major antagonist of activin A, is involved in bone formation
and may have a significant therapeutic potential to trigger
bone regeneration.
The role of follistatin in some of the other essential processes
needed for bone repair such as cell recruitment or vascularization
is suggested but remains unclear. FST has been associated
with angiogenin, a key protein implicated in activation of
endothelial cells and stimulation of new blood vessel growth (Gao
et al., 2007). Nonetheless, whether FST promotes angiogenesis
is uncertain. Some studies have shown that FST induces tumor-
associated angiogenesis (Kozian et al., 1997; Krneta et al., 2006),
but FST was also found to inhibit it (Ogino et al., 2008).
Follistatin is a structurally complex monomeric glycoprotein
widely distributed throughout adult tissues (Patel, 1998). The
FST gene consists of six exons with an alternative splicing site
that generates two major forms and, after further proteolysis
and glycosylation, results in two different variants of the protein.
FST288, which consists of 288 amino acids and FST315, which
consists of 315 amino acids (Phillips, 1998). The FST315 variant
includes an acidic C-terminal tail domain encoded by exon 6,
whereas the FST288 protein ends after exon 5 due to a stop codon
inserted as a result of alternative splicing. Importantly, although
both FST variants contain a heparin-binding sequence, which
affords an ability to bind to cell surface proteoglycans on many
cells, the C-terminal domain in FST315 seems to neutralize the
basic residues of the heparin binding sequence (Schneyer et al.,
2004). Thus, FST315 can only bind to proteoglycans after binding
to activin, which causes a conformational change that exposes
the heparin-binding motif (Hedger et al., 2011). Therefore, in
general FST315 exhibits weak cell-surface binding capability
and is considered the circulating form of the protein, while
FST288 is the tissue-bound variant due to its ability to bind to
heparan-sulfate proteoglycans (Patel, 1998; Gajos-Michniewicz
et al., 2010). The structural differences between both follistatin
variants may have an impact on their properties and ultimately
their regulatory role. In fact, several groups have studied the
pharmacokinetic/pharmacodynamic (PK/PD) relationships and
their effect in muscle regeneration (Datta-Mannan et al., 2013;
Yaden et al., 2014) but unfortunately, most of the published
studies did not specify which FST variant was used (Abe et al.,
2004a; Eijken et al., 2007; Zhu et al., 2011; Bowser et al., 2013;
Kawao et al., 2017).
No receptor for FST has been found but it is known to
bind almost irreversibly to activin A, neutralizing its function
(Sidis et al., 2001; Schneyer et al., 2003). Both variants of FST
inhibit activin A function, although it has been shown that the
affinity of FST288 for activin A is higher than that of FST315
(Hashimoto et al., 2000). Also, FST is able to interact with other
members of the TGF-β superfamily neutralizing or regulating
their functions such as activin B, myostatin and BMPs. With
10-fold lower affinity than for activin A, FST can also bind
to BMP4, 6, and 7 (Glister et al., 2004; Sidis et al., 2006;
Cash et al., 2012). As bone metabolism is regulated mostly by
BMPs and activin A, follistatin seems to play a pivotal role in
bone physiology.
This study has been performed to investigate the use of
FST for bone tissue engineering. In vitro, we have investigated
whether FST is able to attract osteoprogenitor and endothelial
cells from human origin and promote their differentiation.
We then assessed the effect of FST in bone regeneration in a
rat calvarial defect model and loaded two different doses of
both variants of FST—FST315 and FST288—in our previously
developed controlled-delivery system of RCP encapsulated in an
injectable alginate hydrogel (Mumcuoglu et al., 2018).
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MATERIALS AND METHODS
Cell Culture
Human MSCs were obtained from leftover material from
iliac crest biopsies of four juvenile donors (age 9–12 years)
undergoing cleft palate reconstruction surgery with implicit
consent (Erasmus MC medical ethical committee number MEC-
2014-106) and expanded as previously described (Fahmy-Garcia,
2017). Then, cells at passage 4 were used either for migration or
osteogenic differentiation assays.
Primary microvascular endothelial cells (MVECs) were
isolated from the foreskin of three juvenile donors (age 9
mos-4 years) as previously described (Kleinhans et al., 2013)
after their guardians had provided full informed consent
(University of Wurzburg ethical board vote 182/10). Then,
cells were cultured as monolayers in endothelial cell growth
medium MV (ECGM; PromoCell). Cells were passaged at 70–
80% confluence and were used between passages 3 and 5 for
sprouting assays.
HUVECs (Lonza, Walkersville, MD, USA) were cultured at a
density of 5,000 cells/cm2 in endothelial growth medium [EGM-
2 with SingleQuots (Lonza)]. Non-adherent cells were removed
by replacing the medium after 2–3 days. When cells neared
confluency they were used between passages 9 and 12 either for
migration or tube formation assays.
Calvarial-derived Simian Virus-immortalized Human Fetal
Osteoblast (SV-HFO) cells (Chiba et al., 1993) were expanded
and cultured as published previously (Eijken et al., 2006). Briefly,
cells were seeded in phenol-red free α-Minimal EssentialMedium
(a-MEM Gibco, BRL, Paisley, UK), pH 7.5, supplemented with
20mM HEPES (Sigma, St. Louis, MI), penicillin/streptomycin,
1.8mM CaCl2_2H2O (Sigma) and 2% heat-inactivated charcoal-
treated fetal calf serum (FCS). All cell cultures were performed in
5% CO2 at 37
◦C in a humidified atmosphere.
Migration Assay
The effect of FST uponMSC andHUVECmigration was assessed
usingmodified Boyden chambers (polyethylene terephthalate cell
culture inserts, pore size: 8µm in diameter, Millipore-Merck,
NL). The human recombinant FST variants used in this study
were made via CHO-S cell expression using the FST’s native
leader sequences, followed by affinity protein chromatography
using Hi-trap heparin (GE Healthcare Life Science), and desalted
to a 50mM KPO4 buffer (165mM sucrose, 0,01% Tween-20, pH
7.4). SDS-PAGE showed a protein purity higher than 95%.
To analyze MSC migration, α-MEM (Gibco) containing
FST315 [0.8–5 nM (28–175 ng/ml)] was added to the lower
chamber of a 24-well-plate. The doses selected were based in a
previous publication, in which 100 and 500 ng/ml of FST were
used, showing that these range of doses was able to enhance
osteoblast osteogenic differentiation (Eijken et al., 2007), and in
previous non-published studies carried out in our department in
which lower FST doses were tested. αMEM containing PDGF-
AB (20 ng/ml) was used as positive control. The controls used to
investigate MSC migration were also used as controls in another
publication (Fahmy-Garcia, 2017). 6 × 103 MSCs suspended in
a volume of 200 µl α-MEM were added to the upper chamber.
Cell migration was followed at 5% CO2 and 37
◦C in a humidified
atmosphere for 17 h.
To test HUVEC migration, endothelial cell basal medium
(EBM-2, Lonza) containing FST was added to the lower chamber.
5 × 104 HUVECs were added into the upper chamber of
the transwells and incubated at 5% CO2 and 37
◦C in a
humidified atmosphere for 10 h. EGM-2 medium was used
as positive control. The membrane was then washed and the
cells were fixed with 4% formalin and stained with 4
′
, 6-
diamidino-2-phenylindole (DAPI) (100 ng/ml) in the dark for
5min. Cells remaining on the upper surface of the membrane
were mechanically removed with a cotton swab and those which
that had migrated to the lower surface were imaged using
fluorescence microscopy (Zeiss Axiovert 200M Fluorescence
Imaging, Sliedrecht, NL) in five randomfields for eachmembrane
and counted using ImageJ software.
HUVEC Tube Formation Assay
Growth factor-reduced matrigel (Corning, USA) was added to
a 96-wells plate and incubated at 37◦C for 1 h. HUVECs were
trypsinized and resuspended in EBM medium supplemented
with FST315 2-fold concentrated to achieve 28, 70, and 175 ng/ml
as final concentrations. EGM-2 complete medium was used as
positive control and EBM-2 medium as negative control. 15,000
Cells were seeded on top of the matrigel and incubated at 37◦C
in the presence of 5% CO2 in a humidified atmosphere. Tube
formation was imaged after 4, 6, and 24 h of incubation. The
results were analyzed using ImageJ software.
3D-Culture Spheroid Assay
To generate the spheroids, 250,000 MVECS were suspended in
40ml of Vasculife R© complete medium (Lifeline, Germany) with
10ml of methyl cellulose [MethocelTM (Dow, USA)], seeded
in non-adherent round-bottom 96-well-plates (100 µl/well) and
incubated overnight at 37◦C and 5% CO2 in a humidified
atmosphere. The following day spheroids (500 cells approx.
per spheroid) were harvested, transferred to a 50ml tube and
centrifuged (3min, 500 g). Supernatant was removed and the
pellet was covered with 5ml of MethocelTM. Immediately prior
to use, collagen preparation was made by 3.3ml pepsin-extracted
type I collagen (Rat tail collagen High Concentration, type 1,
BD Biosciences, USA) solubilized in 1.7ml 0.1% acetic acid and
0.5ml Medium 199 (10x) (Sigma). 0.5Ml of NaOH 0.2N was
used to reach a neutral PH. Collagen preparation was mixed
with the spheroid-containing methocel solution and seeded in
24-well-plates (1 ml/well). Plates were placed into an incubator
to let the collagen gel polymerize for 30min. Then, collagen gels
were overlaid with 200 µl medium containing FST315 10-fold
concentrated to achieve a final concentration of 28 ng/ml. VEGF
at 27.5 ng/ml was used as positive control and basal medium as
negative control. After 24 h of culture, cell invasion was visualized
using a ZEISS Axiovert 25 microscope at 10x magnification.
Osteogenic Differentiation
Osteogenic differentiation assays were performed on MSCs
and SV-HFOs. 3000 cells/cm2 (MSCs) or 9000 cells/cm2 (SV-
HFOs) were seeded in α-MEM in 12-well-plates. For MSCs,
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the medium was replaced after 24 h with complete osteogenic
medium; DMEM High Glucose (Gibco) with 10% FCS,
1.5µg/mL fungizone, 50µg/mL gentamicin, 25µg/mL ascorbic
acid-2-phosphate, 10mM β-glycerophosphate, and 0.1µM
dexamethasone. For SV-HFOs, medium was replaced after
48 h with osteogenic differentiation medium consisting of
phenol-red free α-MEM (Gibco) supplemented with 20mM
HEPES (Sigma, MO, USA), streptomycin/penicillin, 1.8mM
CaCl2·2H2O (Sigma), 2% heat-inactivated charcoal-treated FCS,
0.1µMdexamethasone and 10mM β-glycerophosphate. To both
cultures FST315 (28, 70, and 175 ng/ml) was added during
each medium refreshment. The experiment was carried out
until onset of mineralization, monitored by measuring calcium
concentration in the culture supernatant. For biochemical
analyses, medium was collected and cells were scraped from the
culture dish in PBS containing 0.1% Triton X-100. Supernatants
were stored at −80◦C. Cell lysates were thawed and sonicated
on ice in a sonifier cell disruptor (Soniprep 150, MSE, London,
UK) or in a water-bath sonifier (Ultrasonic Cleaner CD-4800,
Norville, UK) before analysis.
Alkaline Phosphatase (ALP) Activity and Protein
Measurement
ALP activity was performed as described previously (Lowry
et al., 1954). Briefly, it was assayed by determining the release
of paranitrophenol from paranitrophenylphosphate (pNPP) in
the SV-HFO cell lysates as previously described (Fahmy-Garcia,
2017). Absorption was measured on the Wallac 1420 Victor2
plate reader at 405 nm. For standards, ALP (10 U/ml) from
bovine kidney (Sigma) was used.
Protein was measured in cell lysates using the BCA protein
assay (PierceTM BCA Protein assay, Thermo Scientific, Rockford,
IL) according to manufacturer’s instructions.
Mineralization
To quantify the calcium content, cell lysates were incubated for
48 h in 0.24M HCl at 4◦C. For analysis of calcium concentration
in the culture medium, supernatant was collected and measured
directly from day 9 onwards. In both cases, calcium content was
colorimetrically determined after addition of 1M ethanolamine
buffer (pH 10.6), 19.8mM 8-hydroxyquinoline and 0.35mM
0-cresolphtalein complexone, at 595 nm on the Wallac 1420
Victor2. Besides, to assess that calcium deposition was, in fact,
observed due to the osteogenic differentiation of the cultured
cells and not just due to a mere calcium precipitation, MSCs
and SVHFOs were also cultured in osteogenic medium but in
the absence of dexamethasone. The results showed that, without
the addition of dexamethasone, calcium deposition was not
detectable (Supplementary Figure 1).
For von Kossa staining, cell cultures were fixed for 15min in
4% formaldehyde. After fixation, cells were washed five times
with distilled water. Subsequently, calcium was stained by 5%
(w/v) silver nitrate solution (Sigma, 85228) for 30min under a
60W light. Next, the culture plate was rinsed with distilled water
and dehydrated with ascending concentrations of ethanol (70, 96,
and 100%). Subsequently, ethanol was removed, and cell culture
plates were air-dried and imaged using inverted microscope
(Olympus CKX41, Zoeterwoude, NL).
Quantification of Follistatin and Activin A
Quantification of both human FST and human activin was
measured using the follistatin DuoSet ELISA kit and the activin
A Duoset ELISA kit (R&D Systems). Briefly, 48–72 h after
replacement, conditioned medium was collected until onset of
mineralization and stored at−80◦C. The ELISAs were performed
according to the manufacturer’s protocol.
Preparation of the Hydrogel Formulation
for Protein Release and in vivo Studies
Recombinant Collagen Peptide (RCP) Microspheres (MS) with
an average size of 50µm were produced by emulsification
using calcium carbonate (CaCO3) as described previously
(Mumcuoglu et al., 2017). Pronova SLG20 (sterile alginate where
over 60% of themonomer units are guluronate) was ordered from
Novamatrix (Sandvika, Norway) and was dissolved in 0.9% sterile
sodium chloride to create 2% w/v solution.
Thirty-four milligram of calcium containing microspheres
were incubated overnight at 4◦C with FST315, FST288, or
BMP-2. The recombinant human bone morphogenetic protein-
2 (rhBMP-2, amino acids 283–396 plus an N-terminal Met-
Ala) was expressed in Escherichia coli, isolated from inclusion
bodies, renatured and purified, as previously described (Kirsch
et al., 2000), and it was kindly provided by Dr. Joachim Nickel
(Fraunhofer IGB, Germany). For release assays, 85 µl of FST288
or FST315 at a concentration of 112.5µg/ml was added to
the MS to achieve a final concentration of 1.48 µg in the
final formulation. For in vivo studies, FST288 and FST315 at
152µg/ml and 15.2µg/ml were added overnight to the MS to
achieve a concentration of 20 and 2µg/ml. Eighty-five microliter
of 380µg/ml BMP-2 was added to the MS, resulting in a
concentration of 50µg/ml within the final formulation. After
overnight incubation, on top of swollen particles, 507 µl of SLG
was added. Then, the mixture was supplemented with 53 µl
of 0.06M fresh glucono delta lactone (GDL) solution (Sigma).
GDL was used to dissolve the CaCO3 so that alginate could
be crosslinked and increase the mechanical property of the
formulation. The prepared formulation was incubated overnight
at 4◦C to equilibrate. Next day, the formulation was mixed again
prior to in vitro and in vivo studies.
Release of FST315 and FST288 From the Hydrogel
Formulation
The formulations were prepared as described above; 100 µl from
the hydrogel with 1.48 µg of either one of the both variants
of FST was added to each well of 24-well-plate inserts with
0.4µm pore size. One milliliter DMEM with 10% FBS and 1%
Penicillin/Streptomycin per well was added to reservoir plate.
The plates were incubated at 37◦Cunder constant agitation at 300
rpm. At each time point the medium was collected and replaced
with fresh medium. The collected release media was analyzed
by duoset FST ELISA kit (R&D) according to manufacturer’s
protocol. As positive control, 100 µl of 1.48µg/ml FST288 and
FST315 solution were added to the inserts without hydrogel
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constructs and 1ml medium was added to bottom wells of the
transwell plate. At each time point 1ml medium was collected
and changed with fresh medium.
In vivo Study
All animal experiments were performed with prior approval
of the ethics committee for laboratory animal use (protocol
#EMC 116-15-04).
Twenty-six Sprague Dawley (SD) male rats (Envigo, NL) at 12
weeks old were used in this study to evaluate bone formation.
The animals were randomly assigned and housed in pairs in
a specific pathogen-free environment and allowed to adapt to
the conditions of the animal house for 7 days before starting
the study. The animals were maintained at 20–26◦C on a 12 h
dark/light cycle with ad libitum access to standard rat chow and
water. To evaluate the effect of FST288, FST315, and BMP-2, the
proteins were loaded in the alginate formulation. Forty microliter
of the protein loaded-composite was injected in the defect. Two
different concentrations of FST315 and FST288 were loaded in
the defects, 800 and 80 ng (n = 9 defects). BMP-2 was used as
positive control and the concentration loaded per defect was 2
µg (n = 3 defects). As negative control, biomaterials without
FST were implanted (n = 10 defects). Each animal received
two implants in bilateral defects. Animals were euthanized with
CO2 and the specimens were harvested for further analysis
10 weeks after implantation. The biomaterial only control
used in this experiment was also used as control in another
publication (Mumcuoglu et al., 2018) to reduce the number of
experimental animals.
Surgical Procedure and Fluorochrome Labeling
The rat calvarial defect was performed as previously described
(Spicer et al., 2012). After general anesthesia using 2.5%
isoflurane, the animals received intraperitoneal injections of
0.05 mg/kg of buprenorphine (Temgesic R©, Indivior, UK) for
perioperative analgesia and 5 ml/kg sterile normal saline to
account for fluid losses. The animal skulls were shaved and
disinfected with ethanol swabs. Then, an incision was made
through the skin of the calvarium and periosteum, and full-
thickness flaps were reflected. The defect was irrigated with 0.1ml
of 1% xylocaine with 1:200,000 epinephrine (AstraZeneca, NL)
along the sagittal midline of the skull. Under copious sterile saline
irrigation, two 5-mm-diameter bone defects were prepared with
a trephine bur (Fine Science Tools, Germany) in each animal
and any debris or bone chips were removed. The defects were
treated with the biomaterial loaded with FST, BMP-2 or the
biomaterial alone as described above. Then the periosteum and
the skin over it were repositioned and sutured with polylactic
acid sutures (Vycril 4.0, Ethicon, Johnson Prod., São José
dos Campos, Brazil). All animals received three postoperative
doses of buprenorphine for analgesia every 10 h during the
next days. Four weeks postoperative, rats were subcutaneously
injected with 25 mg/kg of Calcein (Sigma) in a 2% sodium
bicarbonate solution. Fluorochrome label was analyzed using a
light/fluorescence microscope with a filter block (Zeiss Axiovert
200M Fluorescence Imaging, Sliedrecht, NL).
Micro-CT Analysis
Quantum FXmicro-CT (Perkin Elmer, Waltham, MA, USA) was
used to image animals biweekly until the end of the experiment.
To image the bone formation in vivo the following parameters
were used; Field of view: 30mm, Voltage: 90 kV, Current: 160
µA, Scan Time: 3min. To image the implants after retrieval, a
field of view of 20mm and a scan time of 4.5min were used.
Mineral volume and bonemineral density (BMD) weremeasured
on basis of calibration scanning, using two phantoms with known
density (0.25 and 0.75 g/cm3; Bruker Micro-CT) under identical
conditions. For image processing, analysis software was used
(Mayoclinic, Rochester, MN, USA), threshold levels were set
to 0.12 g/cm3.
Histological Evaluation
Ten weeks after implantation, the relevant part of the skull was
removed and fixed in neutral buffered 4% formalin solution for 3
days, dehydrated in graded ethanol solution from 70 to 100%, and
finally embedded inmethyl methacrylate resin. Sections of 10µm
were generated along the long axis of the cylindrical samples on a
sawMicrotome system (Leica 4 SP1600, Germany). Samples were
stained with von Kossa and Goldner’s trichrome as previously
described (Gruber and Gruber, 1992; Fahmy-Garcia, 2017).
Statistical Analysis
Data were analyzed with IBM Statistics 21 (SPSS) and GraphPad
software (GraphPad, San Diego, USA). Migration, osteogenesis
and angiogenesis were analyzed using a linear mixed model; the
different conditions (different doses of the proteins studied) were
considered a fixed parameter and the donors (experiments) as
a random factor. Ex vivo data were also analyzed using a linear
mixed model. Data are presented indicating the mean ± SD and
a value of p < 0.05 was considered to be statistically significant.
FST release data were analyzed using a Student’s T-test, while
in vivo micro-CT data were analyzed using two-way analysis of
variance. If the overall differences were significant, differences
between groups were analyzed by Bonferroni post hoc test. Data
are presented indicating the mean± SEM.
RESULTS
Follistatin Attracts Both MSC and HUVEC
Cells in vitro
To determine if follistatin could recruit osteoprogenitor cells and
endothelial cells to the site of injury, we assessed its ability to
attract MSCs and HUVECs. FST significantly stimulated MSC
migration compared to plain medium control at all doses tested;
1.68, 1.857, and 1.581-fold increase, respectively (p = 0.009, p
= 0.001, p = 0.002) (Figure 1A). Migration of HUVECs toward
FST-containing medium was less pronounced than in MSCs, and
only reached significance at the medium dose (1.28-fold increase
of migration compared to control, p= 0.036) (Figure 1B).
Follistatin Promotes Neovascularization
and Angiogenesis in vitro
Formation and expansion of the vasculature within the newly
formed tissue are the crucial steps in neovascularization, and
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FIGURE 1 | Effect of follistatin upon MSC and HUVEC in a migration assay. (A) Average migration of MSCs exposed to several doses of follistatin (FST315) relative to
the negative control (n = 4 donors in duplicate). (B) Average migration of HUVECs exposed to several doses of follistatin (FST315) relative to the negative control (n =
3 independent experiments in duplicate). The bars represent the mean ± SD.
therefore, in bone repair. Several in vitro assays were performed
to mimic the different steps of the vascularization process. To
determine the capability of FST to promote vasculogenesis in
vitro, HUVECs were seeded on matrigel coated plates in the
absence or presence of FST. FST significantly triggered the
formation of tube-like structures in an inverse dose-dependent
manner, showing 1.6-fold increase when the lowest dose was
supplied compared to the basal medium (p= 0.014) (Figure 2A).
As positive control, endothelial cells were also treated with EGM-
2 complete medium. EGM-2 medium stimulated formation of
tube-like structures 1.7 times more than the basal medium (data
not shown).
To assess whether 28 ng/ml of FST is also able to induce
sprouting angiogenesis, spheroid-sprouting assays were done
using MVECs. The spheroid serves as starting point for the
growth of capillary-like sprouts. FST stimulated the formation
of endothelial cell sprouts from the spheroids, showing more
than 2-fold increase in the number of sprouts compared to
control (Figure 2B) and with a similar potency to VEGF (data
not shown). In summary, these data indicate that FST is able to
stimulate the distinct mechanisms involved in the formation of
the vascular network.
Follistatin Does not Stimulate MSC
Osteogenic Mineralization, but Stimulates
Committed Osteoblast Mineralization
The osteogenic properties of FST were studied in MSCs
stimulated toward the osteoblastic lineage as well as in fetal
calvarial-derived committed pre-osteoblasts (SV-HFO). The
addition of FST did not affect mineralization of MSCs, as shown
by quantitative measurement of calcium deposition and von
Kossa mineral staining (Figure 3A). Interestingly, adding FST
to the pre-osteoblast culture had a direct positive effect on the
mineralization process at any of the tested doses, showing a
minimum of 2-fold increase compared to the control (osteogenic
differentiation medium) (Figure 3B).
Additional experiments also indicated a positive effect of FST
on committed osteoblast differentiation, as is shown via activity
of the enzyme alkaline phosphatase. Alkaline phosphatase (ALP)
is expressed during osteoblastic differentiation and plays a key
role in bone mineralization (Wennberg et al., 2000). When the
lowest dose of FST was applied to the pre-osteoblast culture, a
small but significant increase in ALP activity was observed before
mineralization started (day 9). At day 16, FST enhanced ALP
activity in all concentrations tested (Figure 3B).
Follistatin Production Changes During
Osteogenic Differentiation
To regulate cellular processes, such as extracellular matrix
mineralization, two follistatin molecules encircle activin,
neutralizing its receptor binding sites (Thompson et al., 2005).
We measured the levels of FST and activin produced during
the different phases of osteogenic differentiation in MSC and
SV-HFO cultures by ELISA. FST was produced in high quantities
by MSCs at the onset of mineralization (day 16) and its release
significantly decreased during full mineralization (Figure 4A).
Activin production levels did not significantly differ during
MSC culture, but remained low (at least 15 times lower than the
FST levels at the same time points) (Figure 4B). Unlike MSCs,
SV-HFOs are already osteogenic–committed cells and therefore,
mineralization occurs earlier than in MSCs. In SV-HFOs,
the production of FST decreased from day 9 onwards during
osteogenic differentiation (Figure 4A), a similar pattern to what
was observed in MSCs, though earlier in culture. Activin levels
were undetectable in SV-HFO cultures.
FST288 Release Is Lower Than FST315
Release From the Alginate-MS Hydrogel
It is generally believed that controlled-release systems are optimal
for bone formation as they offer spatiotemporal control to mimic
the native healing cascades. The previously developed alginate-
MS hydrogel was shown to provide sustained protein release
(Mumcuoglu et al., 2018). We first evaluated the release profile
of FST288 and FST315 from this formulation. After 4 weeks, the
cumulative amount of FST315 and FST288 found in the medium
was quantified. To correct for the effect of protein sticking to
the plate and membrane, as well as its degradation over time,
1.48µg/ml of FST288 and FST315 were added to the upper part
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FIGURE 2 | Effect of follistatin on neovascularization. (A) Effect of follistatin (FST315) on vasculogenesis. Total number of nodes was quantified (n = 3 experiments in
triplicate). Next to the graph, representative pictures of tube-like structures are shown after 6 h incubation in the presence and absence of FST (scale bar: 1,000µm).
(B) Effect of FST315 on angiogenesis. MVEC spheroids were embedded in collagen and incubated for 24 h. The total number of sprouts per spheroid w/o the addition
of FST at 28 ng/ml dose are plotted in the graph (n = 10 individual spheroids per experimental group). Next to the graph, representative pictures of cell spheroids in
the presence and absence of FST are shown after 24 h incubation (scale bar: 400µm). The bars show the mean ± SD.
of the transwells without the hydrogel formulation. For FST288
671.60 ± 220.6 ng (mean ± SEM) and for FST315 688.5 ± 78.2
ng (mean± SEM) were detected, meaning that both FST variants
have a similar degradation rate. There are important differences
between both FST variants; unlike FST288, FST315 has a C-
terminal tail containing several acidic residues, which decrease its
heparin affinity.Most likely this differencemight affect the release
profile of the FST variants. In fact, when the release of both FST
variants from the alginate-MS formulation was studied over 4
weeks, significant differences were observed between the release
of FST315 and FST288. 555± 58 Ng of FST315 was released from
the formulation, while only 169.4± 6.8 ng of FST288was released
during the same period. Therefore, the amount of FST315 exuded
to the medium was three times more than the amount of FST288
(p < 0.001) (Figure 5). The numbers indicated that the majority
of FST315 was released from the hydrogel formulation, contrary
to FST288, which was mostly retained in it.
FST315 and FST288 Do Not Improve Bone
Healing in Calvarial Defects, but Show a
More Homogeneous Bone Formation Than
Controls
Given the promising effects of FST on migration, osteogenesis
and vascularization in vitro, we decided to investigate whether
FST is able to promote bone repair and if there are differences
between FST315 and FST288 to induce bone formation. To do so,
both FST variants loaded in alginate-MS hydrogel were injected
into 5mm calvarial defects. In vivo longitudinal microCT-
scans were performed biweekly to monitor the mineralized
bone volume (BV) within the defects, and normalized to the
BV observed in healthy SD male rats of the same age. At
week 2, the positive control with BMP-2 loaded biomaterial
exhibited the same amount of bone volume as the healthy
animals, which translated into full defect healing at the end of
the experiment (Supplementary Figure 2). Implantation of the
biomaterial alone led to 66% bone volume compared to healthy
animals at the end of the experiment (Figures 6A,B).
No major differences between FST-treated animals and the
ones treated with only the biomaterial were observed during
10-weeks follow up. At week 2, 30% of the bone volume
observed in healthy animals was already achieved in all the
tested conditions. During the time course of the experiment,
mild differences in terms of BV were observed between the FST
variants. However, at week 10 the overall BV observed was similar
in all conditions, varying between 65 and 71% of the defect
area (Figures 6A,B).
The retrieved implants were also scanned ex vivo, which
allows longer scan times and finer resolution. Bone mineral
density of the formed bone did not differ significantly between
conditions (Figure 7A) and was comparable to the density found
in the calvaria of healthy animals (0.77± 0.03 g/cm3, mean ±
SD, n=4 animals). The bone coverage of the defect oscillated
between 40 and 47% of the total defect area (Figure 7B),
which is slightly lower than the coverage found in the in
vivo longitudinal microCT-scans at 10 weeks. This difference is
due to motion artifacts and the settings used in longitudinal
microCT-scans on live animals. Either way, microCT-scans
showed that bone formation not only occurred around the
edge of the defect, but also in the central area. Interestingly,
more areas with mineralization were observed in the FST
conditions, but overall mineral density did not differ from
the controls (Figure 7C). On histology, circular regions were
observed in all the conditions. These regions have a similar size
to the microspheres used (∼50µm) and in the FST conditions
were surrounded by immature ECM, while in the controls,
were mostly surrounded by fibrous tissue (Figure 7C). This
is more evident when analyzing the mineralization pattern by
measuring calcein fluorochrome incorporation. In the controls,
the label was mostly present on the outer periphery of the
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FIGURE 3 | Effect of follistatin on osteogenic differentiation. Human MSCs and osteoblasts were induced to mineralize in the absence or continuous presence of
follistatin (FST315). (A) Quantification of calcium deposition (nmol/ cm2) in the MSC extracellular matrix at the onset of mineralization relative to control (osteogenic
differentiation medium) (n = 4 donors performed in triplicate). Donor dependently, mineralization started between 18 and 22 days of culture. Representative pictures of
the Von Kossa staining at the onset of mineralization (scale bar: 500µm). (B) Left graph: alkaline phosphatase (ALP) activity (mU/ cm2) during SV-HFO culture with and
without continuous FST treatment at day 9 (gray bars) and 16 (black bars) of culture. Results are shown relative to day 9 control. Right graph: Quantification of calcium
deposition (nmol/ cm2) in the SV-HFO extracellular matrix at day 16 relative to control (n = 3 experiments performed in triplicate). The bars show the mean ± SD.
formed bone and hardly any signal was found in the inner
side at 4 weeks. In the FST-treated samples the label was
found in both periphery and inward area, indicating a broader
andmore homogeneousmineralization progression (Figure 7D).
Besides, in the control samples alginate was still visible, whereas
in the FST-treated samples this was undetectable (Figure 7C
and Supplementary Figure 3). Histological analysis also showed
blood vessels in growth in all the conditions tested (Figure 7C
and Supplementary Figure 3).
DISCUSSION
This study investigated the use of FST for bone repair. We have
found that FST was able to recruit and differentiate endothelial
cells (ECs), promote cell sprouting and the formation of tube-
like structures in vitro. Furthermore, FST was also able to recruit
osteoprogenitor cells and to enhance committed osteoblast
differentiation and mineralization in vitro. However, when FST
was loaded in our previously developed slow-release formulation
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FIGURE 4 | Production of follistatin and activin A by MSCs and osteoblasts. FST (A) and activin A (B) levels were measured in supernatant of MSC and SV-HFO that
were induced to mineralize until onset of mineralization. Production was corrected for cell lysate protein content. The bars show the mean ± SD. **p < 0.01 and ***p
< 0.001.
FIGURE 5 | In vitro release of FST288 compared to FST315. The cumulative
release of FST288 and FST315 from the alginate-MS formulation in DMEM
with 1% P/S detected by ELISA is demonstrated over 4 weeks. Data are
presented indicating the mean ± SEM. Statistical difference at 28 days of
cumulative release analyzed by Student’s t-test, p < 0.001.
(Mumcuoglu et al., 2018) and implanted in a calvarial defect
model, bone repair was not improved in 10 weeks’ time.
FST is known to be upregulated by migrating ECs (Kozian
et al., 1995); however, the chemokinetic effect of follistatin upon
ECs was not studied yet. Our results have shown that FST is able
to stimulate HUVEC migration when exogenously added to the
culture. Furthermore, to assess its effect upon ECs differentiation,
we have used two different in vitro models-−3D spheroid-
sprouting assays and tube-formation assays—to investigate both
angiogenesis and vasculogenesis as two of the pivotal processes of
the vasculature formation. Interestingly, the formation of tube-
like structures seemed to be inversely dose-dependent and FST
was able to significantly promote both processes when 28 ng/ml
(0.8 nM) was added to the culture in the absence of VEGF or
any other co-stimulatory factor. In vitro studies have shown that
both follistatin and activin are distinctly expressed during the
different phases of angiogenesis by bovine aortic ECs (BAECs)
and MVECs (Kozian et al., 1995; Glienke et al., 2000). A few
studies investigated the effect of activin (25–50 ng/ml) inducing
vasculogenesis upon BAECs and sinusoidal ECs (SECs), showing
a positive effect when combined with VEGF but contradictory
results when used alone to enhance tubulogenesis (Endo et al.,
2004; Maeshima et al., 2004). Krneta et al explored the effect
of FST and activin in a sprouting angiogenesis assay, showing
that FST at 120 ng/ml was able to promote EC sprouting almost
at the same level as FGF, while activin addition at 50 ng/ml
did not enhance sprouting more than basal control (Krneta
et al., 2006). The combination of FGF and activin significantly
decreased sprouting (Krneta et al., 2006). In vivo, a few papers
have shown that FST improved a neovascularization when used
on skeletal muscle injury in mice (Zhu et al., 2011) and promoted
angiogenesis in the rabbit cornea, especially when combined with
FGF (Kozian et al., 1997). It would be interesting to further
study this synergistic effect on bone repair. Although we did
not specifically study the vascularization processes in our in vivo
bone defect model, we have found blood vessels in growth in all
the treated samples, suggesting that follistatin does not interfere
with the natural cascade of events needed for the formation
of the vasculature and consequently, it does not have an anti-
vasculogenic effect.
Whether FST could attract MSCs and induce bone formation
was not studied before. In our in vitro study we have
demonstrated that FST is able to recruit MSCs. Minor differences
were observed between doses, meaning that probably a low
dose of FST is enough to promote a chemotactic response upon
MSCs. We also investigated the effect of FST upon MSCs and
osteoblasts under osteogenic conditions. It is known that FST is
highly expressed in developing bone tissues, mainly in osteoblasts
(Inoue et al., 1994); however, the effect of FST on osteoblast
mineralization was unclear due to conflicting results observed
when supplied to mouse and human osteoblast cultures (Abe
et al., 2004a; Eijken et al., 2007). In our in vitro study, FST further
enhanced osteogenic differentiation in committed osteoblasts
and not in MSCs.
The stimuli involved in MSC’s differentiation to osteoblastic
cells may differ from those needed to convert pre-osteoblasts
into mature osteoblasts. For example, it is well-known that
TGF-β-Smad signaling is crucial in the early phases of osteogenic
differentiation, however, it inhibits osteoblast maturation
and mineralization (Wu et al., 2016). Consequently, different
signal inputs are needed at different stages of the osteoblast
differentiation pathway. Our findings suggest that FST’s
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FIGURE 6 | In vivo µCT analysis of rat skulls implanted with FST288 and FST315 over time. (A) Representative in vivo µCT images of the skulls at 2, 4, 6, 8, and 10
weeks after implantation (scale bar: 2mm) of either biomaterial alone or loaded with FST288 or FST315. In the representative µCT images of both FST variants the
right defect was loaded with 800 ng of FST and the left defect was loaded with 80 ng of FST. (B) Graphical representations of in vivo µCT analysis. Bone volume was
normalized to animals without surgical intervention. The effect of the formulation loaded with FST288 (left graph) and FST315 (right graph) was compared to the effect
of the use of the biomaterial alone as control group.
osteogenic effect might be sensitive to which differentiation
stage the osteoprogenitor cells are. Previous studies have shown
that once FST is synthesized, it remains in the extracellular
matrix, exerting an antifibrotic-effect (Nakamura et al., 1991;
Maeshima et al., 2014). Indeed, based on previous studies in
which have been shown that activin A suppresses osteoblast
mineralization by changing the ECM composition and maturity
(Eijken et al., 2007; Alves et al., 2013), and in our results, we
might conclude that FST is not an osteogenic factor per se, but
a factor that enhances the mineralization process through its
involvement changing the ECM composition while it remains
in it. We must remember that FST can only exert its function
indirectly, by binding to other molecules and neutralizing their
function. Its main antagonist is activin, but FST can also bind
to BMPs, with much lower affinity (Glister et al., 2004). Abe
et al demonstrated in their study that administration of FST to
rat mandibular osteoblasts did not cause significant changes in
bone nodule number. BMP-2 facilitated the secretion of FST and
this increase in FST interfered with BMP-2 action decreasing
bone nodule formation (Abe et al., 2004a). Eijken et al showed in
their study that, while FST prevented activin from binding to its
receptor, it had no effect on basal or BMP2-induced signaling in
human osteoblasts (SV-HFO) (Eijken et al., 2007). Besides, there
are several studies that investigated the effect of the addition
of activin to osteogenic differentiation of human NHOst cells,
showing that its addition strongly inhibited the mineralization
process (Eijken et al., 2007; Pearsall et al., 2008). As no receptor
has been found for FST, it is widely assumed that FST exerts
its regulatory function via antagonizing other proteins with
a pivotal role in bone physiology. FST is able to bind almost
irreversibly to activin, and with lower affinity to other members
of the TGFβ family such as bone morphogenetic proteins. In
our in vitro experiments, both MSCs and SVHFOs secreted high
levels of FST but much lower levels of activin under osteogenic
conditions. In fact, the secretion of FST was at least 15-fold
higher than the secretion of activin at the same time-points.
This amount of FST is much greater than the 2:1 molar ratio
needed to neutralize all the activin produced by the cells. The
addition of FST to the culture media enhanced mineralization
of SVHFOs, but not of MSCs. These findings suggest that FST,
even when it is found in a much higher concentration than
activin, has a positive effect on osteoblast mineralization but
does not affect MSC mineralization. Follistatin can antagonize
BMP functions as well as those of the activins, and in view
of the sharing of type II receptors between activins and
bone morphogenetic proteins (BMPs), further studies should
investigate the secretion of these proteins at the different
phases of MSC’s osteogenic differentiation and the interplay
between them.
To investigate the ability of FST to promote bone repair
in an orthotopic model, FST was loaded within an in situ
gelling alginate-based delivery system and implanted in a rat
calvarial defect model. We hypothesized that FST, based on
previous in vivo studies and on our in vitro results, may
have a positive effect on bone formation. We have used two
different FST variants (FST288 and FST315) to assess whether
their structural variations -which modulate their properties
such as the ability to bind to the cell surface-, could lead
to differences between variants in terms of bone repair. In
fact, in vitro release from the biomaterial showed that during
4 weeks, only 25% of FST288 was released to the medium
compared to 80% of FST315.
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FIGURE 7 | Newly formed bone tissue at 10 weeks of healing. (A) Bone density observed by ex vivo µCT analysis in the different conditions after implant harvesting.
(B) Percentage of defect filling by newly formed mineralized tissue analyzed by ex vivo µCT. Mean is indicated as the line plotted in the middle of the graphs ± SD. (C)
Representative pictures of rat skulls implanted with the biomaterial w/o the addition of the FST variants at 10 weeks. Histological analysis includes von Kossa and
Goldner’s trichrome staining. Von Kossa staining was used to distinguish mineralized tissue (black) (scale bar: 2.5mm), while Goldner’s trichrome staining was used to
determine bone histomorphometry. The square grid delimitates the selected magnified area for each image that is shown with Goldner’s trichrome staining (scale bars
are 250µm and 50µm, respectively), showing erythrocytes (red/purple), nuclei (blue/ gray), alginate remains (alg), formed bone (B), and fibrous tissue (FT). Immature
ECM is indicated by yellow arrows and regions where the microspheres have been likely degraded are indicated by black arrows. (D) Representative fluorescence
images of the central region of the explants showing calcein fluorochrome incorporation in the newly formed bone tissue at 10 weeks post-implantation (scale bar:
500µm) with or without the addition of the FST variants. Fluorescence images are combined with bright-field images of the same area.
Two different doses of FST288 and FST315 were loaded within
the biomaterial to elucidate if there is a limiting concentration
of FST that leads to bone repair enhancement and whether FST
excess prevents bone repair. FST doses used (800 ng and 80
ng per implant) were based on both our in vitro studies and
the literature. Serum levels of FST are found in the ng range
in mice (Barakat et al., 2008), and our results show that the
lowest dose of FST used in the in vitro experiments (28 ng/ml)
improved crucial processes involved in bone formation such as
cell migration, osteogenesis, and neovascularization. However,
none of the variants improved bone formation compared to the
biomaterial in 10 weeks’ time. Besides, during the degradation of
the biomaterial the protein is released and the differences in FST
concentrations of the separate defects may become minor.
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Timing of secretion of FST during bone repair seems crucial.
When a demineralized matrix was subcutaneously implanted
in rats, FST was highly expressed during the initial stages of
osteogenesis but decreased along with differentiation (Funaba
et al., 1996). Injections of FST in the implants 10 days
after implantation resulted in lower calcium content in the
implants suggesting that the endochondral ossification process
was retarded or inhibited (Funaba et al., 1996). Nagamine et al
showed that neither FST nor activin were expressed in osteogenic
cells at the periosteum or at the cortical bone in the intact
femurs of the rat (Nagamine et al., 1998). Interestingly, in a
fractured-femur FST was highly expressed during the first stages
of bone healing in osteogenic cells, as well as in the ECM of
the periosteum and proliferating chondrocytes, while activin A
was almost undetectable in those regions. Furthermore, Activin
A was detected especially around osteoclast-like cells on the
surface of the newly-formed trabecular bone (Nagamine et al.,
1998), which is in line with previous publications (Inoue et al.,
1994). Altogether indicates that the expression of FST during
different phases of both intramembranous and endochondral
ossification is important. However, the role of FST in bone repair
has been investigated either using ectopic models or long bone
fracture models (Funaba et al., 1996; Nagamine et al., 1998) in
which the mechanisms of bone formation differ considerably
from the events taking place in the development of the flat
bones of the skull. It is difficult to compare in vitro and in
vivo studies, but our in vitro experiments have shown that
FST effects do not respond to a classical dose-response curve;
MSC migration and mineralization may need different FST
doses that may not fit with FST release timing and dosage
from the biomaterial chosen in this study. In fact, when the
alginate formulation was implanted alone, residual alginate was
still visible 10 weeks post implantation, whereas in the FST-
treated samples this phenomenon was not detected. In FST-
treated samples mineralization occurred both on the outer and
inner area of the defect, contrary to what was observed in the
controls, where calcein was mostly incorporated on the outer
periphery of the defect. An alginate-based formulation was used
as FST carrier to achieve FST’s slow release, but FST appears
to be an early player in bone formation. As we have previously
mentioned, our data and the literature suggest that FST exerts
its function through the ECM, enhancing its mineralization.
The slow release alginate-based system may not be optimal for
bone repair when loaded with FST and might influence the FST
effect upon ECMmineralization due to a suboptimal FST release
timing. Alginate has been widely used for bone tissue engineering
due to its biocompatibility, easy handling and degradation
properties (Venkatesan et al., 2015). We have previously used
RCP encapsulated in an injectable alginate hydrogel ectopically,
and the formulation releasing BMP-2 effectively promoted bone
formation. However, when used in bone defect repair, alginate
seemed to not only delay the protein release, but also cell and
cytokine infiltration within the defects (Mumcuoglu et al., 2018).
Activin A has been identified as a pivotal molecule during the
initial inflammatory response (Hedger et al., 2011), which can
be also provoked by surgical stress. Interestingly, FST increased
in the circulation several hours after activin A and it is believed
that the increase observed in FST levels was partly responsible for
the clearance of activin A from the bloodstream (Hedger et al.,
2011). In our study, alginate, due to its chemostatic effect, could
have prevented or delayed the cascade of events needed for bone
repair such as the influx of inflammatory cells and growth factors,
or the clearance of activin A from the injury site. Bleeding could
also have affected the biomaterial physical-chemical properties.
Certainly, it would be interesting to assess whether FST addition
shows a positive effect in a bone defect when used in a different
type of delivery system with a faster release. The affinity to
bind cell surface receptors dictates the main biological action
of FST. FST315 is considered to act more in an endocrine
fashion whereas FST288 does it in an autocrine manner. In
fact, FST315 has been used systemically as a therapeutic agent
to treat skeletal muscle diseases: however, it exhibits rapid
clearance kinetics. Consequently, newly engineered FST315
variants with improved pharmacokinetic properties have been
developed, showing promising results in the treatment of several
musculoskeletal injury models (Datta-Mannan et al., 2013; Yaden
et al., 2014). In our study we aimed to enhance in situ bone
formation and in the view of our release studies and the greater
affinity for cell surface proteoglycans of FST288, the use of this
FST variant in a rapid release system is intriguing, and could
prompt the assessment of new strategies in bone defect repair.
To our knowledge, this is the first study that instead
of focusing in osteogenic differentiation to investigate FST
possible role in bone formation, assesses the effect of FST upon
chemotaxis and vasculogenesis as well due to their essential role
in bone formation, and directly evaluates its possible influence
in an orthotopic bone defect such as calvarial-defect. FST plays
an important role in bone metabolism, mostly acting as activin
controller but also regulating the function of other members of
the TGFβ family (Funaba et al., 1996; Gajos-Michniewicz et al.,
2010). However, FST action spans so many different processes
that its effect in particular cellular events involved in bone
formation was unclear. In summary, this study has shown that
FST is able to stimulate cell recruitment, vasculogenesis, and
osteogenesis; vital processes for a successful bone regeneration.
Using the calvarial defect model we could not show a clear
improvement in bone repair with FST -which can be due to
several causes such as poor bone-forming capacity, underdosage
and suboptimal release kinetics among others-, though we
observed a more homogeneous mineralization. There is still
a lack of knowledge about the role of FST in the acute phase
reaction and the effect of its administration in the early phases
of bone repair. Therefore, to move on further using growth
factor-based therapies, mechanistic approaches should be taken
in consideration to investigate how and in which extent FST,
as well as its interaction with other proteins, such as activins
and BMPs, regulates key processes in bone metabolism and
repair. Besides, the optimal release kinetics of FST must be
investigated in vivo to successfully translate its use into bone
tissue engineering based therapies.
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